We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Real‐world experience of rIX‐FP prophylaxis at dosing intervals of 14 days or more in adult patients with haemophilia B in Italy – Results from IDEAL Part B.
- Authors
Coppola, Antonio; Peyvandi, Flora; Banov, Laura; Cultrera, Dorina; Margaglione, Maurizio; Tosetto, Alberto; Valdrè, Lelia; Schiavetti, Irene; Loraschi, Anna; Castaman, Giancarlo
- Abstract
The article discusses a study conducted in Italy that evaluated the use of recombinant factor IX-albumin fusion protein (rIX-FP) as a treatment for adult patients with hemophilia B. The study found that rIX-FP prophylaxis was effective in reducing bleeding episodes and required fewer infusions compared to previous treatments. The most common dosing regimen was every 14-15 days, with one patient using a 21-day regimen. The study concluded that rIX-FP is a flexible and effective treatment option for adult patients with hemophilia B, but further research is needed to assess long-term outcomes. It is important to consider physical activity levels and lifestyle when personalizing prophylaxis regimens.
- Subjects
HEMOPHILIACS; BLOOD coagulation factor IX; CLINICAL trials; HEALTH facilities; ADULTS
- Publication
Haemophilia, 2024, Vol 30, Issue 4, p1067
- ISSN
1351-8216
- Publication type
Article
- DOI
10.1111/hae.15074